Press releases
* (R) = Regulatory press releases
22 Sep, 2022
(R) Cantargia reports first non-squamous NSCLC patient treated with nadunolimab, Keytruda® and chemotherapy
15 Sep, 2022
(R) Cantargia: Oral presentation of new preclinical CAN10 efficacy data in systemic sclerosis at ACR Convergence
31 Aug, 2022
(R) New number of shares and votes in Cantargia
30 Aug, 2022
Cantargia publishes preclinical data on strong anti-tumor efficacy of nadunolimab in combination with chemotherapy
30 Aug, 2022
(R) Cantargia publishes half year report
17 Aug, 2022
Invitation to presentation of Cantargia’s report for the second quarter of 2022 on August 30 at 3.00 p.m. CET
12 Aug, 2022
(R) Cantargia announces final outcome of the company’s significantly oversubscribed rights issue
25 Jul, 2022
